Abstract: A system embodied in an article of clothing for synchronizing one or more breast-pumping sessions of an individual (such as a mother) and milk consumption by a second individual (such as a baby or infant) is described. In particular, based on measurements of a volume of the collected milk as a function of time and received information specifying milk consumption by the second individual as a function of time, a control circuit may determine a need for milk. Then, the control circuit may provide feedback based on the determined need for milk that synchronizes the one or more breast-pumping sessions and the milk consumption. For example, the feedback may alert the individual to initiate a breast-pumping session and/or may provide a signal to a breast pump that initiates a breast-pumping session.

Abstract: A system for synchronizing one or more breast-pumping sessions of an individual (such as a mother) and milk consumption by a second individual (such as a baby or infant) is described. In particular, based on measurements of a volume of the collected milk as a function of time and received information specifying milk consumption by the second individual as a function of time, a control circuit may determine a need for milk. Then, the control circuit may provide feedback based on the determined need for milk that synchronizes the one or more breast-pumping sessions and the milk consumption. For example, the feedback may alert the individual to initiate a breast-pumping session and/or may provide a signal to a breast pump that initiates a breast-pumping session.

Abstract: A system for synchronizing one or more breast-pumping sessions of an individual (such as a mother) and milk consumption by a second individual (such as a baby or infant) is described. In particular, based on measurements of a volume of the collected milk as a function of time and received information specifying milk consumption by the second individual as a function of time, a control circuit may determine a need for milk. Then, the control circuit may provide feedback based on the determined need for milk that synchronizes the one or more breast-pumping sessions and the milk consumption. For example, the feedback may alert the individual to initiate a breast-pumping session and/or may provide a signal to a breast pump that initiates a breast-pumping session.

Abstract: A system for synchronizing one or more breast-pumping sessions of an individual (such as a mother) and milk consumption by a second individual (such as a baby or infant) is described. In particular, based on measurements of a volume of the collected milk as a function of time and received information specifying milk consumption by the second individual as a function of time, a control circuit may determine a need for milk. Then, the control circuit may provide feedback based on the determined need for milk that synchronizes the one or more breast-pumping sessions and the milk consumption. For example, the feedback may alert the individual to initiate a breast-pumping session and/or may provide a signal to a breast pump that initiates a breast-pumping session.

Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.

Abstract: A system for synchronizing one or more breast-pumping sessions of an individual (such as a mother) and milk consumption by a second individual (such as a baby or infant) is described. In particular, based on measurements of a volume of the collected milk as a function of time and received information specifying milk consumption by the second individual as a function of time, a control circuit may determine a need for milk. Then, the control circuit may provide feedback based on the determined need for milk that synchronizes the one or more breast-pumping sessions and the milk consumption. For example, the feedback may alert the individual to initiate a breast-pumping session and/or may provide a signal to a breast pump that initiates a breast-pumping session.

Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.

Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorder.

Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract: Disclosed herein are methods for generating proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using these proteases to treat diseases in which the target proteins are involved with. Cleaving certain target proteins at certain substrate sequences with a protease is a method for treating these pathologies.

Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

Abstract: MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis.

Abstract: Disclosed herein are methods for generating proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using these proteases to treat diseases in which the target proteins are involved with. Cleaving certain target proteins at certain substrate sequences with a protease is a method for treating these pathologies.